CN114616226B - 吡啶衍生物作为tmem16a调节剂用于呼吸系统病症的治疗 - Google Patents

吡啶衍生物作为tmem16a调节剂用于呼吸系统病症的治疗 Download PDF

Info

Publication number
CN114616226B
CN114616226B CN202080053192.6A CN202080053192A CN114616226B CN 114616226 B CN114616226 B CN 114616226B CN 202080053192 A CN202080053192 A CN 202080053192A CN 114616226 B CN114616226 B CN 114616226B
Authority
CN
China
Prior art keywords
hydroxy
amino
pyridine
phenyl
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080053192.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN114616226A (zh
Inventor
S·科林伍德
C·巴克斯顿
J·D·哈格雷夫
P·英格拉姆
T·B·斯科菲尔德
A·谢赫
C·斯廷森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TMEM16A Ltd
Original Assignee
TMEM16A Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1910607.9A external-priority patent/GB201910607D0/en
Priority claimed from GBGB2005739.4A external-priority patent/GB202005739D0/en
Application filed by TMEM16A Ltd filed Critical TMEM16A Ltd
Publication of CN114616226A publication Critical patent/CN114616226A/zh
Application granted granted Critical
Publication of CN114616226B publication Critical patent/CN114616226B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
CN202080053192.6A 2019-07-24 2020-07-24 吡啶衍生物作为tmem16a调节剂用于呼吸系统病症的治疗 Active CN114616226B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP1910607.9 2019-07-24
GBGB1910607.9A GB201910607D0 (en) 2019-07-24 2019-07-24 Compounds
GBGB2005739.4A GB202005739D0 (en) 2020-04-20 2020-04-20 Compounds
EP2005739.4 2020-04-20
PCT/GB2020/051778 WO2021014166A1 (en) 2019-07-24 2020-07-24 Pyridine derivatives as tmem16a modulators for use in the treatment of respiratory conditions

Publications (2)

Publication Number Publication Date
CN114616226A CN114616226A (zh) 2022-06-10
CN114616226B true CN114616226B (zh) 2025-03-04

Family

ID=71948615

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080053192.6A Active CN114616226B (zh) 2019-07-24 2020-07-24 吡啶衍生物作为tmem16a调节剂用于呼吸系统病症的治疗

Country Status (16)

Country Link
US (1) US20220235006A1 (https=)
EP (1) EP4003516A1 (https=)
JP (1) JP7583022B2 (https=)
KR (1) KR20220063162A (https=)
CN (1) CN114616226B (https=)
AU (1) AU2020317036A1 (https=)
BR (1) BR112022001164A2 (https=)
CA (1) CA3145120A1 (https=)
CL (1) CL2022000147A1 (https=)
CO (1) CO2022002022A2 (https=)
CR (1) CR20220072A (https=)
IL (1) IL290035A (https=)
MX (1) MX2022000841A (https=)
PE (1) PE20221441A1 (https=)
PH (1) PH12022550181A1 (https=)
WO (1) WO2021014166A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20221441A1 (es) * 2019-07-24 2022-09-21 Tmem16A Ltd Derivados de piridina como moduladores de tmem16a para su uso en el tratamiento de afecciones respiratorias
WO2026038890A1 (ko) * 2024-08-13 2026-02-19 광주과학기술원 신규한 치환된 피리딘 유도체 화합물, 이의 제조방법, 및 이를 유효성분으로 포함하는 호흡기 질환의 예방 또는 치료용 약학적 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019145726A1 (en) * 2018-01-26 2019-08-01 Enterprise Therapeutics Limited Compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050176767A1 (en) 2003-10-30 2005-08-11 Laval Chan Chun Kong Pyridine carboxamide and methods for inhibiting HIV integrase
US11358947B2 (en) * 2017-04-17 2022-06-14 The Regents Of The University Of California Substituted 2-acylamino-cycloalkylthiophene-3-carboxylic acid arylamides as inhibitors of calcium-activated chloride channel TMEM16A
PE20221441A1 (es) * 2019-07-24 2022-09-21 Tmem16A Ltd Derivados de piridina como moduladores de tmem16a para su uso en el tratamiento de afecciones respiratorias

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019145726A1 (en) * 2018-01-26 2019-08-01 Enterprise Therapeutics Limited Compounds
CN111683926A (zh) * 2018-01-26 2020-09-18 企业治疗学有限公司 化合物

Also Published As

Publication number Publication date
CN114616226A (zh) 2022-06-10
KR20220063162A (ko) 2022-05-17
CO2022002022A2 (es) 2022-06-10
CR20220072A (es) 2022-06-29
MX2022000841A (es) 2022-06-08
BR112022001164A2 (pt) 2022-03-15
JP7583022B2 (ja) 2024-11-13
PH12022550181A1 (en) 2023-01-16
JP2022541311A (ja) 2022-09-22
WO2021014166A1 (en) 2021-01-28
US20220235006A1 (en) 2022-07-28
IL290035A (en) 2022-03-01
CA3145120A1 (en) 2021-01-28
EP4003516A1 (en) 2022-06-01
CL2022000147A1 (es) 2022-10-07
AU2020317036A1 (en) 2022-03-17
PE20221441A1 (es) 2022-09-21

Similar Documents

Publication Publication Date Title
CN111683926B (zh) 化合物
CN114616226B (zh) 吡啶衍生物作为tmem16a调节剂用于呼吸系统病症的治疗
US20200361871A1 (en) Compounds
US12552770B2 (en) Compounds for treating respiratory disease
CN114269433B (zh) 用于治疗呼吸系统疾病的tmem16a的调节剂
HK40069002A (en) Pyridine derivatives as tmem16a modulators for use in the treatment of respiratory conditions
CN114929683B (zh) 作为钙激活氯化物通道调节剂的吡啶衍生物
HK40067765A (en) Modulators of tmem16a for treating respiratory disease
HK40075169A (en) Pyridine derivatives as calcium-activated chloride channel modulators
CN116745267A (zh) 用于治疗呼吸系统疾病的苯并咪唑衍生物
HK40042091A (en) Tmem16a modulators
HK40042091B (en) Tmem16a modulators
HK40067764B (zh) 用於治疗呼吸系统疾病的化合物
HK40067764A (en) Compounds for treating respiratory disease
HK40067765B (zh) 用於治疗呼吸系统疾病的tmem16a的调节剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40069002

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant